Compare Genuine Parts Company (GPC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs IDEXX Laboratories, Inc. — how do they compare? Genuine Parts Company trades at $126.99 (market cap $17.67B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.32% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GPC | IDXX | |
|---|---|---|
Market Cap | $17.67B | $40.43B |
Volume | 1,079,458 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $766.68 |
52-Week Low | $92.47 | $504.70 |
Typical Hold Time | 75 Days | 46 Days |
Enterprise Value | $23.76B | $41.32B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $127.02, up 1.28% on the day, with a bullish technical signal and analyst consensus price target of $145.75. Recent quarterly earnings show two beats and one miss, while the company prepares for a planned separation of its automotive and industrial units in Q1 2027. Revenue has grown steadily to $24.3B in 2025, but net income margin is thin at 0.13%.
The outlook is supported by the corporate split catalyst and dividend stability, but risks include compressed profitability and rising debt-to-asset ratios. Wall Street sentiment is mixed, with 43% buy ratings, yet the stock offers value with a P/S of 0.71 and exposure to aging vehicle trends.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
